metallothionein has been researched along with Ganglioneuroblastoma* in 1 studies
1 other study(ies) available for metallothionein and Ganglioneuroblastoma
| Article | Year |
|---|---|
TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.
To identify markers of response to therapy in neuroblastic tumors.. A total of 58 patients with neuroblastic tumor (38 neuroblastomas, 13 ganglioneuroblastomas and 7 ganglioneuromas) were included in the study. TP53, BCL-2, p21Waf1/Cip1 and metallothionein were included as a biologic approach to tumor differentiation, response to therapy and prognosis.. Patients who died of disease had the following immunophenotype: BCL-2 (9 of 10), nuclear TP53 (7 of 10) and metallothionein (7 of 10). TP-53 expression was related to clinical stage (p = 0.062) and disease outcome (p = 0.0218). All patients in whom treatment failed expressed metallothionein (3 of 3).. TP53, BCL-2, p21Waf1/Cip1 and metallothionein had limited value reflecting tumor maturation (differentiation) or predicting response to therapy. Only nuclear TP53 accumulation may be relevant in patient's prognosis. Topics: Adolescent; Adult; Biomarkers, Tumor; Cell Differentiation; Child; Cyclin-Dependent Kinase Inhibitor p21; Female; Ganglioneuroblastoma; Humans; Male; Metallothionein; Neuroblastoma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2008 |